Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Psoriatic Arthritis Clinical Trial

Official title:

The Predictive Value of Monocyte Chemoattractant Protein -1 in the Development of Cardiovacular Events in Psoriatic Arthritis Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05637905
• Other study ID #: MCP-1
• Status: Not yet recruiting
• Start date: January 2023
• Est. completion date: June 2025

Study information

• Verified date: November 2022
• Source: Assiut University
• Contact: Amira Anas, Master
• Phone: 01066633924
• Email: amiraanas60[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction .

2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Description:

Psoriatic arthritis (PSA) is an autoimmune disease arising from the interply between proinflamatory cytokines

[1]and external stimuli in genetically predisposed individuals.[2]

• The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.[3]

• Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .[4] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration[5].

Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. [6] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors [7].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease [8] is important for the timely introduction of therapy [9].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium [10].

• The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium[11].

• MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6. It affects the functions of the surrounding immune effector cells in locally thickened intima.[12]

• During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 [13]. MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA [14].

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: June 2025
• Est. primary completion date: March 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PsA patients (age = 18years) who fulfilled the CASPAR classification criteria[15]for psoriatic arthritis

Exclusion Criteria:

• PsA patients with

1. infection.

2. bone marrow disorders.

3. other autoimmune diseases.

4. diabetes.

5. hypertention .

6. hyperlipidemia.

7. liver diseases.

8. renal diseases.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MCP-1	:Evaluate serum levels of monocyte chemoattractant protein-1(MCP-1) in relation to echocardiographic changes in patient with psoriatic arthritis.	two month
Secondary	Echocardiography	b.Detect subclinical cardiovascular affaction in patient with psoriatic arthritis.	two month

External Links

•   .E. L. Potter, S. Ramkumar, H. Kawakami et al., "Association of asymptomatic diastolic dysfunction assessed by left atrial strain with incident heart failure,"JACC: Cardiovascular Imaging, vol. 13, no. 11, pp. 2316-2326, 2020.
•   .Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-12
•   .Moll JM, Wright V Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.CrossRefPubMedGoogle Scholar.
•   1.V.Chandran,F.Abji,A.V. Perruccio et al.,"Serum-basedsoluble markers difffferentiate psoriatic arthritis from osteoarthritis," Annals of the Rheumatic Diseases,vol.78, no.6, pp.796-801,2019.
•   A. B. Gottlieb and J. F. Merola, "Axial psoriatic arthritis: an update for dermatologists," Journal of the American Academy of Dermatology, vol. 84, no. 1, pp. 92-101, 2021
•   A. L. Carvalho and C. M. Hedrich, "The molecular pathophysiology of psoriatic arthritis-the complex interplay between genetic predisposition, epigenetics factors, and the microbiome," Frontiers in Molecular Biosciences, vol. 8, p. 662047, 2021.
•   A. Rana, V. K. Mahajan, K. S. Mehta et al., "Cardiomyopathy and echocardiographic abnormalities in Indian patients with psoriasis: results of a pilot study," International Journal of Clinical Practice, vol. 75, no. 3, p. e13756, 2021.
•   C. Papadopoulou, V. Corrigall, P. R. Taylor, and R. N. Poston, "The role of the chemokines MCP-1, GRO-a, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques," Cytokine, vol. 43, no. 2, pp. 181-186, 2008.
•   D. E. Furst and J. S. Louie, "Targeting inflammatory pathways in axial spondyloarthritis," Arthritis Research & Therapy, vol. 21, no. 1, p. 135, 2019.
•   Lin, V. Kakkar, and X. Lu, "Impact of MCP -1 in atherosclerosis," Current Pharmaceutical Design, vol. 20, no. 28, pp. 4580-4588, 2014.
•   Lories RJ, de Vlam K. Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? Curr Rheumatol Rep 2012; 14: 375-382.
•   P. Aukrust, B. Halvorsen, A. Yndestad et al., "Chemokines and cardiovascular risk," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 1909-1919
•   P. S. Pagel, J. N. Tawil, B. T. Boettcher et al., "Heart failure with preserved ejection fraction: a comprehensive review and update of diagnosis,pathophysiology, treatment, and perioperative implications," Journal of Cardiothoracic and Vascular Anesthes
•   Risk Reclassification According to Cardiovascular Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
•   Y. R. Woo, C. J. Park, H. Kang, and J. E. Kim, "The risk of systemic diseases in those with psoriasis and psoriatic arthritis:from mechanisms to clinic," International Journal of Molecular Sciences, vol. 21, no. 19, p. 7041, 2020.